Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants During an Outbreak in the Democratic Republic of the Congo

During the 2018-2020 Ebola virus disease (EVD) outbreak, residents in Goma, Democratic Republic of the Congo, were offered a two-dose prophylactic EVD vaccine. This was the first study to evaluate the safety of this vaccine in pregnant women. Adults, including pregnant women, and children aged ≥1 year old were offered the Ad26.ZEBOV (day 0; dose 1), MVA-BN-Filo (day 56; dose 2) EVD vaccine through an open-label clinical trial. In total, 20,408 participants, including 6635 (32.5%) children, received dose 1. Fewer than 1% of non-pregnant participants experienced a serious adverse event (SAE) following dose 1; one SAE was possibly related to the Ad26.ZEBOV vaccine. Of the 1221 pregnant women, 371 (30.4%) experienced an SAE, with caesarean section being the most common event. No SAEs in pregnant women were considered related to vaccination. Of 1169 pregnancies with a known outcome, 55 (4.7%) ended in a miscarriage, and 30 (2.6%) in a stillbirth. Eleven (1.0%) live births ended in early neonatal death, and five (0.4%) had a congenital abnormality. Overall, 188/891 (21.1%) were preterm births and 79/1032 (7.6%) had low birth weight. The uptake of the two-dose regimen was high: 15,328/20,408 (75.1%). The vaccine regimen was well-tolerated among the study participants, including pregnant women, although further data, ideally from controlled trials, are needed in this crucial group.

References

Ilunga Kalenga O, Moeti M, Sparrow A, Nguyen V, Lucey D, Ghebreyesus T . The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018-2019. N Engl J Med. 2019; 381(4):373-383. DOI: 10.1056/NEJMsr1904253. View

Patel A, Bann C, Kolhe C, Lokangaka A, Tshefu A, Bauserman M . The Global Network Socioeconomic Status Index as a predictor of stillbirths, perinatal mortality, and neonatal mortality in rural communities in low and lower middle income country sites of the Global Network for Women's and Children's Health.... PLoS One. 2022; 17(8):e0272712. PMC: 9380930. DOI: 10.1371/journal.pone.0272712. View

Milligan I, Gibani M, Sewell R, Clutterbuck E, Campbell D, Plested E . Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA. 2016; 315(15):1610-23. DOI: 10.1001/jama.2016.4218. View

Jalloh M, Sengeh P, Ibrahim N, Kulkarni S, Sesay T, Eboh V . Association of community engagement with vaccination confidence and uptake: A cross-sectional survey in Sierra Leone, 2019. J Glob Health. 2022; 12:04006. PMC: 8876869. DOI: 10.7189/jogh.12.04006. View

Roozendaal R, Hendriks J, Van Effelterre T, Spiessens B, Dekking L, Solforosi L . Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. NPJ Vaccines. 2020; 5(1):112. PMC: 7747701. DOI: 10.1038/s41541-020-00261-9. View

Watson-Jones D, Kavunga-Membo H, Grais R, Ahuka S, Roberts N, Edmunds W . Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo. BMJ Open. 2022; 12(3):e055596. PMC: 8905941. DOI: 10.1136/bmjopen-2021-055596. View

Kallay R, Doshi R, Muhoza P, Choi M, Legand A, Aberle-Grasse E . Use of Ebola Vaccines - Worldwide, 2021-2023. MMWR Morb Mortal Wkly Rep. 2024; 73(16):360-364. PMC: 11065462. DOI: 10.15585/mmwr.mm7316a1. View

Mizerero S, Wilunda C, Musumari P, Ono-Kihara M, Mubungu G, Kihara M . The status of emergency obstetric and newborn care in post-conflict eastern DRC: a facility-level cross-sectional study. Confl Health. 2021; 15(1):61. PMC: 8356431. DOI: 10.1186/s13031-021-00395-0. View

Olesen A, Westergaard J, Thomsen S, Olsen J . Correlation between self-reported gestational age and ultrasound measurements. Acta Obstet Gynecol Scand. 2004; 83(11):1039-43. DOI: 10.1111/j.0001-6349.2004.00193.x. View

10.

Karita E, Nyombayire J, Ingabire R, Mazzei A, Sharkey T, Mukamuyango J . Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial. Trials. 2022; 23(1):513. PMC: 9207821. DOI: 10.1186/s13063-022-06360-3. View

11.

Anywaine Z, Barry H, Anzala O, Mutua G, Sirima S, Eholie S . Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS Med. 2022; 19(1):e1003865. PMC: 8752100. DOI: 10.1371/journal.pmed.1003865. View

12.

Usman S, Bologna L, Stamidis K . The CORE Group Partners Project in North East Nigeria: Community Engagement Strategies to Combat Skepticism and Build Trust for Vaccine Acceptance. Am J Trop Med Hyg. 2019; 101(4_Suppl):68-73. PMC: 6776099. DOI: 10.4269/ajtmh.19-0143. View

13.

Haddad L, Jamieson D, Rasmussen S . Pregnant Women and the Ebola Crisis. N Engl J Med. 2018; 379(26):2492-2493. DOI: 10.1056/NEJMp1814020. View

14.

Morin I, Morin L, Zhang X, Platt R, Blondel B, Breart G . Determinants and consequences of discrepancies in menstrual and ultrasonographic gestational age estimates. BJOG. 2005; 112(2):145-52. DOI: 10.1111/j.1471-0528.2004.00311.x. View

15.

Schwartz D . Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas. Vaccines (Basel). 2020; 8(1). PMC: 7157486. DOI: 10.3390/vaccines8010038. View

16.

Majola L, Budhram S, Govender V, Naidoo M, Godlwana Z, Lombard C . Reliability of last menstrual period recall, an early ultrasound and a Smartphone App in predicting date of delivery and classification of preterm and post-term births. BMC Pregnancy Childbirth. 2021; 21(1):493. PMC: 8265063. DOI: 10.1186/s12884-021-03980-6. View

17.

Mulinganya G, Malembaka E, Lukula Akonkwa M, Mukendi D, Birindwa E, Maheshe Balemba G . Applying the Robson classification to routine facility data to understand the Caesarean section practice in conflict settings of South Kivu, eastern DR Congo. PLoS One. 2020; 15(9):e0237450. PMC: 7478810. DOI: 10.1371/journal.pone.0237450. View

18.

Dikete Ekanga M, Mitangala P, Coppieters Y, Kirkpatrick C, Kabuyanga Kabuseba R, Simon P . Evolution in caesarean section practices in North Kivu: Impact of caregiver training. PLoS One. 2022; 17(5):e0264251. PMC: 9135218. DOI: 10.1371/journal.pone.0264251. View

19.

Gomes M, de la Fuente-Nunez V, Saxena A, Kuesel A . Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials. Reprod Health. 2018; 14(Suppl 3):172. PMC: 5751665. DOI: 10.1186/s12978-017-0430-2. View

20.

Anywaine Z, Whitworth H, Kaleebu P, PrayGod G, Shukarev G, Manno D . Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. J Infect Dis. 2019; 220(1):46-56. PMC: 6548900. DOI: 10.1093/infdis/jiz070. View